Phase III Clinical Trial Update and New IIH Market Analysis
Filed with ASX · · 6 pages · English
Invex Therapeutics Ltd. on 6ix
Story so far
Earlier from Invex Therapeutics
- Invex Granted European Orphan Drug Designation for TBI
- Invex Receives Regulatory Approval for IIH EVOLVE in France
- Israel Ministry of Health Approval for IIH EVOLVE
- German Approval for IIH EVOLVE Phase 3 Clinical Trial
- Half Year Accounts
Later from Invex Therapeutics
- Invex to close IIH Evolve Phase III Clinical Trial
- Invex issued US patent for Traumatic Brain Injury
- Proposed Capital Return to Shareholders of $14.0 Million
- Invex Granted European Patent for Exenatide in Hydrocephalus
- Invex and Peptron Mutually Terminate Manufacturing Agreement
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics